Copan FecalSwab® receives the 510(k) FDA clearance for molecular use with the BD MAX™ Enteric & Extended Enteric Bacterial Panels
Copan announces the 510(k) FDA clearance of its Copan FecalSwab® for collecting and transporting stool samples to be processed with BD Enteric Bacterial Panel and BD Extended Enteric Bacterial Panel on the BD MAX™ System. This clearance opens new molecular diagnostic opportunities for customers who already use FecalSwab® to maintain enteric pathogens’ vitality for microbial culturing.
Copan Group: from the efforts against the pandemic to the investments for a sustainable development
Despite the unpredictable scenario caused by the pandemic, 2021 was another positive year for Copan. Behind a turnover of 395 million euros, the company has adopted a global industrial strategy and investments aimed at sustainable development. Following these principles, the Group is preparing to face the challenges of the post-pandemic market.
ECCMID 2022: Copan unveils its WISE approach to sample management
Copan took the chance of the first in-person ECCMID of the last two years to give a name to its holistic approach to preanalytics. From sample collection to image analysis and data interpretation, meet Copan’s WISE approach, which brings any sample to improved diagnostics.
COPAN Resolves U.S.I.T.C. Unfair Competition Investigation with Several Manufacturers and Distributors of Imported Flocked Swabs
Copan announces the resolution of its United States International Trade Commission complaint with many companies involved, filing a joint request with each settling respondent seeking termination from the ongoing investigation as a result of the settlements.
U.S.I.T.C. Institutes Unfair Competition Investigation of Imported Flocked Swabs and Kits
On Friday, August 27, 2021, the United States International Trade Commission instituted an unfair importation investigation against several manufacturers and distributors of imported flocked swabs and products containing the flocked swabs and infringing several of our US-issued patents.
Moving ahead: Copan announces a major rebranding and launches a new website
Time of change for Copan. The Italian preanalytics company announced the completion of an extensive rebranding initiative which includes a new logo and a new website with updated functionalities. The rebranding aims to represent at best the company values and offer an improved customer experience.
Copan strengthens its operations in the Americas with a millionaire investment
Copan announces a $ 78 investment to expand its Puerto Rican production site. The project – partially financed by Puerto Rico’s Government – will bring Copan production and distribution capacity closer to the American market, strengthening the company’s presence in the US and the rest of the Americas.
Copan, putting Covid-19 challenges behind and setting up for the post-pandemic scenario
With an email to the main distributors, Copan group’s CEO describes how the ramp-up of Covid-19-related products has been concluded, and how the company is now reorganizing to face post-pandemic challenges.
Last Tuesday, Copan partners received an email signed by Copan’s CEO Stefania Triva herself. Certainly, it was not the first email they received from the leader in preanalytics last year. Still, this time the communication tried to put a full stop to pandemic-related struggles, informing about the accomplishment of 2020 common goals and reorganizing the company and its network for the years to come.
Copan Response to the Pandemic and our Efforts to Fight COVID-19 Worldwide
When supermarket shelves across the country were suddenly bare — and people were clamoring for essentials like toilet paper — everyone learned a little more than they wanted to about the importance of supply chains.